Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in Schizophrenia

Jones, Peter B.; Barnes, Thomas R. E.; Davies, Linda; Dunn, Graham; Lloyd, Helen; Hayhurst, Karen P.; Murray, Robin; Markwick, Alison; Lewis, Shôn

doi:10.1001/archpsyc.63.10.1079

articleArchives of General PsychiatryOct 1, 2006Closed access

Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in Schizophrenia

PBPeter B. Jones TRThomas R. E. Barnes LDLinda Davies GDGraham Dunn HLHelen Lloyd

University of Cambridge · Cambridgeshire and Peterborough NHS Foundation Trust

PubMed

Indexed incrossrefpubmed

Abstract

Objective

To test the hypothesis that in people with schizophrenia requiring a change in treatment, SGAs other than clozapine are associated with improved quality of life across 1 year compared with FGAs.

Design

A noncommercially funded, pragmatic, multisite, randomized controlled trial of antipsychotic drug classes, with blind assessments at 12, 26, and 56 weeks using intention-to-treat analysis.

Citation impact

1,106

total citations

FWCI: 61.07
Percentile: 100%
References: 34

Citations per year

Authors

9

Topics & keywords

Topics

Keywords

Schizophrenia (object-oriented programming)
Clozapine
Randomized controlled trial
Antipsychotic
Quality of life (healthcare)
Adverse effect
Psychiatry
Medical prescription

No related works found for this paper.